• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Viemed Healthcare Announces Share Repurchase Program

    6/9/25 8:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care
    Get the next $VMD alert in real time by email

    LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026.

    Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ("the Common Shares") from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025.

    The Company intends to repurchase Common Shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase.

    Casey Hoyt, Viemed's Chief Executive Officer, noted, "Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business. We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan's Medical that is expected to close in the third quarter of this year. Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies. With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives."

    The price paid for the Common Shares will be the market price at the time of purchase, plus applicable brokerage fees, or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of Common Shares that will be repurchased under the program, if any. The Company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The Common Shares purchased by the Company will be cancelled.

    ABOUT VIEMED HEALTHCARE, INC.

    Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.

    Forward-Looking Statements

    Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations regarding the amount and timing of any potential repurchases of Common Shares, the funding sources for such repurchases, the availability of Common Shares for such repurchases, and the anticipated benefits to shareholders of such repurchases, as well as about its pending acquisition of Lehan's Medical Equipment, such as expected purchase price, contingent payments, closing date, funding sources, and anticipated synergies and other benefits are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

    For further information, please contact:

    Investor Relations

    [email protected]

    Tripp Sullivan

    SCR Partners, LLC

    615-942-7077

    Trae Fitzgerald

    Chief Financial Officer

    Viemed Healthcare, Inc.

    337-504-3802



    Primary Logo

    Get the next $VMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VMD

    DatePrice TargetRatingAnalyst
    11/3/2021$13.00 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $VMD
    Financials

    Live finance-specific insights

    See more
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details

      LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0dOJVhdb Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com. ABOUT VIE

      4/22/25 4:30:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Record 2024 Financial Results

      LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): Net revenues for the quarter ended December 31, 2024 reached a new Company record of $60.7 million representing an increase of $10.0 million, or 20%, over net revenues reported for the comparable quarter ended Decembe

      3/10/25 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13D/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:58 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13G/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:32 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed by Viemed Healthcare Inc.

      SC 13G - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/14/24 4:51:42 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    SEC Filings

    See more
    • Viemed Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      6/9/25 8:12:57 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      6/5/25 5:15:49 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Viemed Healthcare Inc.

      10-Q - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      5/7/25 4:50:18 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viemed Healthcare Announces Share Repurchase Program

      LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ("the Common Shares") from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases o

      6/9/25 8:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast Ideas Investor Conference on June 11th in New York

      LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed's presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company's website: http://viemed.com/investors. ABOUT VIEMED HEALTHCARE, INC. Viemed is an

      6/3/25 8:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Leadership Updates

    Live Leadership Updates

    See more

    $VMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

      LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

      5/6/25 8:30:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

      LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama. "We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand Home

      4/2/24 9:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

      LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD, TSX:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the "Meeting") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company. Election of Directors The eight candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's m

      6/13/23 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Viemed Healthcare with a new price target

      RBC Capital reiterated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      11/3/21 9:01:34 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Royal Bank of Canada initiated coverage on Viemed Healthcare with a new price target

      Royal Bank of Canada initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/11/21 8:08:09 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital initiated coverage on Viemed Healthcare with a new price target

      RBC Capital initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/5/21 8:11:16 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Heltz Sabrina bought $19,977 worth of shares (2,820 units at $7.08), increasing direct ownership by 7% to 41,040 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      5/14/24 5:25:11 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smokoff Timothy sold $91,364 worth of shares (11,865 units at $7.70), decreasing direct ownership by 13% to 79,786 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      3/17/25 4:42:59 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Operating Officer Zehnder William Todd converted options into 35,791 shares, covered exercise/tax liability with 8,147 shares and returned $74,089 worth of shares to the company (8,948 units at $8.28), increasing direct ownership by 7% to 273,973 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:28:06 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Fitzgerald Trae converted options into 13,060 shares, covered exercise/tax liability with 2,962 shares and returned $27,034 worth of shares to the company (3,265 units at $8.28), increasing direct ownership by 9% to 82,994 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:27:56 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care